StockData
Alterity Therapeutics Ltd logo

Alterity Therapeutics Ltd (ATHE) stock

ATHENasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRNAF
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Aug 28, 2026Score 5/30
$1.86−0.09 (-4.85%)

Close on Nov 17, 2026Market cap $33.80MP/E –Yield –

Alterity Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2026 it was A$17.63M, up 22.4% from the year before. Over ten years it grew 6.3% a year on average. The highest annual figure on record is A$18.64M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2026Jun 30, 2026A$17.63M+22.4%
FY2025Jun 30, 2025A$14.40M-22.7%
FY2024Jun 30, 2024A$18.64M+41.3%
FY2023Jun 30, 2023A$13.20M-10.5%
FY2022Jun 30, 2022A$14.75M+20.0%
FY2021Jun 30, 2021A$12.28M+21.6%
FY2020Jun 30, 2020A$10.10M-22.2%
FY2019Jun 30, 2019A$12.98M+93.8%
FY2018Jun 30, 2018A$6.70M+17.5%
FY2017Jun 30, 2017A$5.70M-40.5%
FY2016Jun 30, 2016A$9.59M–

More Alterity Therapeutics figures

See a number that looks wrong?